Jeff Bird, M.D., Ph.D.
Managing Director, Sutter Hill Ventures
Jeff Bird focuses on healthcare, including biotechnology and medical devices. In addition to Forty Seven, Inc., recent series A investments include XIOS Therapeutics (small molecular immune-oncology). In the genomics space, Jeff is a co-investor with Illumina in Helix (consumer genomics marketplace) and GRAIL (cancer screening test). Jeff was CEO and an investor at Verinata Health (noninvasive prenatal diagnosis). After their acquisition by Illumina in early 2013, he served as their GM for a year. He is currently a board member at NuGen Technologies (research reagents), Portola Pharmaceuticals (PTLA,a spin-out of Cor/Millennium focused on cardiovascular therapeutics), Restoration Robotics (aesthetic surgery devices), and Teneobio (next generation antibodies). He also represents the firm’s investments in Acceleron Pharmaceuticals (XLRN, metabolic therapeutics) and Pacific Biosciences (PACB, DNA sequencing). Jeff was formerly a director at Horizon Pharma (HZNP), Akarx Inc., (acquired by MGI Pharma in 2008), BARRX Medical, Inc. (acquired by Covidien in 2012) and Idun Pharmaceuticals, (acquired by Pfizer in 2005). Jeff was previously Senior Vice President, Business Operations at Gilead Sciences, where he worked from 1988 to 1990 and then 1992 to 2000. He was primarily responsible for several alliances with major pharmaceutical companies and helped Gilead to acquire NeXstar in a $550 million transaction. His commercial responsibilities included direct sales in the US and Europe. Jeff received a degree in Biological Sciences from Stanford in 1982, a Ph.D. in Cancer Biology in 1988 and a M.D. in 1992 from Stanford Medical School.
Dennis Henner, Ph.D.
Chief Scientific Advisor, Clarus
Dennis Henner, Ph.D., is the Chief Scientific Advisor of Clarus, prior to this he served as Managing Director of Clarus for 12 years beginning in 2005 with the firm’s inception. Prior to Clarus, Dr. Henner was a General Partner at MPM Capital, a healthcare venture capital firm. He has over 30 years of direct industry and investment experience within the healthcare sector. From 1981 to 2001, Dr. Henner was an executive at Genentech where he held various positions including Senior Vice President of Research, and was a member of Genentech's executive committee. Dr. Henner received his Ph.D. from the Department of Microbiology at the University of Virginia and did postgraduate training at the Scripps Clinic and Research Foundation. Currently Dr. Henner is on the Board of Directors at Cleave Biosciences, Forty Seven Sciences and Imago BioSciences. Dr. Henner is also a member of the Board of Trustees of Reed College. Past Board seats include Aerie Pharmaceuticals (NASDAQ: AERI), Cellerant, Ceregene, Inc. (acquired by Sangamo BioSciences), CoMentis, Inc., Ferrokin Biosciences (acquired by Shire), KaloBios, Pelikan Technologies, Rinat (acquired by Pfizer), Rigel (NASDAQ:RIGL), SARcode (acquired by Shire). Synergia, and Tercica (acquired by Ipsen).
Jonathan MacQuitty, Ph.D.
Venture Partner, Lightspeed Venture Partners
Jonathan MacQuitty focuses on life science and healthcare investments at Lightspeed. He was formerly a partner at Abingworth, a trans-Atlantic life science venture capital firm, heading up the firm’s West Coast office. From May 2015 to April 2017, he was the founding CEO of Forty Seven Inc. Jonathan is on the board of a number of Lightspeed portfolio companies and is Chairman of Personalis, another portfolio company, which is commercializing human genomic analysis for cancer research and diagnosis. Jonathan has spent over 30 years in life science companies and in the venture capital sector that finances them. He joined Abingworth in 1999 as President of the firm’s US subsidiary based in Menlo Park, CA. Between1988 until its acquisition in 1997, he was founding CEO of GenPharm International, a Bay Area biotech company developing a human sequence antibody platform. Prior to that he held business development positions at Genencor and Genentech. His directorships have included Acorda (now NASDAQ), Dicerna (now NASDAQ), Guava (acquired), Gynesonics, Labcyte, Myelos (acquired), Palo Alto Health Sciences, ParAllele BioScience (acquired), Quantum Dot (acquired), SFJ Pharma, Sosei (now listed in Tokyo), and Sunesis (now NASDAQ). He has also served on the Board of the Biotechnology Industry Organization (BIO). Jonathan has an MA in Chemistry from Oxford University, a PhD in Chemistry from the University of Sussex, and an MBA from Stanford University.
Ravi Majeti, M.D., Ph.D.
Associate Professor of Medicine, Chief, Division of Hematology, Stanford University School of Medicine
Dr. Ravi Majeti is an Associate Professor in the Department of Medicine, Chief of the Division of Hematology, and Member of the Institute for Stem Cell Biology and Regenerative Medicine at Stanford University. He was an undergraduate at Harvard, earned his MD and PhD from UCSF, and trained in Internal Medicine at Brigham and Women’s Hospital in Boston. Dr. Majeti completed his Hematology Fellowship at Stanford, and is a board-certified hematologist. While at Stanford, he completed post-doctoral training in the laboratory of Irving Weissman, where he investigated acute myeloid leukemia (AML) stem cells and therapeutic targeting with anti-CD47 antibodies. With Dr. Weissman, he developed a humanized anti-CD47 antibody, initiated first-in-human clinical trials, and in 2015, co-founded Forty Seven Inc. Dr. Majeti established his independent laboratory in 2009 with research focused on the molecular/genomic characterization and therapeutic targeting of leukemia stem cells in human hematologic malignancies, particularly AML. Dr. Majeti is a recipient of the Burroughs Wellcome Fund Career Award for Medical Scientists, the New York Stem Cell Foundation Robertson Investigator Award, and the Leukemia and Lymphoma Society Scholar Award.
Mark McCamish, M.D., Ph.D.
President & CEO of Forty Seven, Inc.
Mark is President and Chief Executive Officer of Forty Seven, Inc. He is an international expert in biosimilars and biologics. Mark is passionate about mentoring and developing people while focusing on meeting patient needs through efficient, commercially viable efforts. He is a senior executive with extensive experience at multiple companies including Abbott, Amgen, and Novartis-Sandoz. He led pioneering efforts in filing and launching biosimilars worldwide. He has demonstrated a commercial mindset in establishing research and development strategies leading to approvals and commercial success in multiple therapeutic areas and regulatory categories including biologics, biosimilars, drugs, devices, and medical foods. He held professorships at University of California, Davis and The Ohio State University. After completing his Ph.D. in Human Nutrition from Penn State and MD from UCLA he completed Residency and Fellowship Training at the University of California, Davis. Mark received his bachelor’s degree in exercise physiology form University of California, Santa Barbara.
Partner, Lightspeed Venture Partners
Chris is a founder of Lightspeed Venture Partners. He has 26 years of venture capital experience with investment interests in the areas of enterprise, consumer and medical technologies. Chris has been named to the Forbes Midas List of top venture capital investors 11 times since its introduction in 2001. He has also backed over 10 first-time CEOs who have led their startup companies though successful IPOs. Prior to entering the venture industry, he served in corporate finance and capital markets roles at Goldman, Sachs & Co. after working as a software engineer at IBM. Chris has served as a director of over 30 private and public companies. He holds BS and MS degrees in Computer Science and Electrical Engineering from MIT and an MBA from the Stanford Graduate School of Business.
Irv Weissman, M.D.
Director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine
Director of the Stanford Ludwig Center for Cancer Stem Cell Research.
Dr. Irving L. Weissman, M.D., is the Director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine and Director of the Stanford Ludwig Center for Cancer Stem Cell Research. He is a founder of Forty Seven, Inc. and serves on the Board of Directors. Dr. Weissman was a member of the founding Scientific Advisory Boards of Amgen, DNAX , and T-Cell Sciences. He co-founded, was a Director, and chaired the Scientific Advisory Board at SyStemix, StemCells, Inc, and Cellerant. His research encompasses the biology and evolution of stem cells and progenitor cells. His lab was first to prospectively isolate mouse and human blood stem cells, and he also was a co-isolater of the human brain forming stem cells. At SyStemix and Stem Cells Inc these cells were brought into successful early stage clinical trials. He is also engaged in isolating and characterizing the rare cancer and leukemia stem cells. He discovered that all cancer stem cells express CD47, the ‘don’t eat me’ signal, to overcome prophagocytic signals that arise during cancer development. Dr. Weissman is a member of the National Academy of Sciences, the National Academy of Medicine, and the American Association of Arts and Sciences. He has received many awards, including the, the Pasarow Award in Cancer Research, the California Scientist of the Year, the De Villiers International Achievement Award of the Leukemia Society of America, the Robert Koch Award, the Rosenstiel Award, The Max Delbruck Medal,and the Jessie Stevenson Kovalenko Award of the National Academy of Sciences. He has several honorary doctorates.